Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 397 |
Synonyms | |
Therapy Description |
AMG 397 is a small molecule inhibitor of MCL1 that selectively disrupts the interaction with members of the Bcl2 family, potentially resulting in increased cellular apoptosis, decreased cell viability, and reduced tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 6218). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 397 | AMG-397|AMG397|Murizatoclax | MCL1 Inhibitor 18 | AMG 397 is a small molecule inhibitor of MCL1 that selectively disrupts the interaction with members of the Bcl2 family, potentially resulting in increased cellular apoptosis, decreased cell viability, and reduced tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 6218). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03465540 | Phase I | AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | Terminated | USA | ITA | GRC | FRA | AUS | 1 |